Proteomics International Laboratories has announced a partnership with medical device sales agency Growth Medics to expand the reach of its PromarkerD predictive test for diabetic kidney disease within the EU.
The collaboration is aimed at identifying and selecting EU alliance partners to enhance the distribution of PromarkerD.
Growth Medics will help identify, recruit and manage new partners and customers across Europe for Proteomics.
The engagement is focused on digital marketing efforts to increase the visibility and adoption of PromarkerD.
The partnership will see Growth Medics providing comprehensive business development, marketing and administrative support from its Netherlands office.
Its responsibilities will include representing Proteomics International at trade shows, delivering customer service and providing training.
Initially, the focus will be on fostering new licensing and sales opportunities in the Netherlands, Belgium, Italy and Spain.
Under the fee-for-service agreement, which includes commission-based incentives, Growth Medics will be the sole sales agency for Proteomics International in the targeted European countries.
The two-year engagement can be extended by mutual agreement and includes standard terms, conditions and warranties.
Both parties retain the right to terminate the partnership with six weeks' notice if there is a breach of any material terms.
Proteomics International managing director Richard Lipscombe said: “We believe Growth Medics is an ideal partner to drive the commercialisation of PromarkerD through Europe due to their extensive market knowledge, proven track record, regulatory expertise and strong relationships with key stakeholders.
“This is a material development in our expansion strategy for PromarkerD across the diverse European market.”
The PromarkerD prognostic test, which is CE Mark registered in the EU, was developed to predict future kidney function decline in patients with type 2 diabetes.
Using a simple blood test, the test can detect a unique ‘fingerprint’ of the early disease onset by measuring three serum protein biomarkers, combined with three conventional clinical variables that are routinely available.
The results are integrated into a patient risk report using a cloud-based algorithm.
